Thus, GSH and ATF4 levels in CML cells are the markers to indicate JMF4073 sensitivity and determine the selection of GSH blocker for the combination with JMF4073 in therapy. Here, ATF4 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.